The majority of patients with chronic phase chronic myeloid leukaemia (CP-CML) treated with imatinib achieves cytogenetic disease remission. Molecular monitoring for residual disease has prognostic significance: rising BCR-ABL levels may provide earliest indication that a patient has become resistant to treatment. The emergence of resistance to imatinib has dampened the enthusiasm for this drug. The most common cause of resistance is the selection of leukemic clones mutated in ABL kinase domain due to amino acid substitutions with prevention of appropriate binding of the drug. Amplification and over-expression of BCR-ABL, acquired cytogenetic aberrations and modulation of drug efflux or influx transporters have been reported. These observat...
none20noPURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associat...
Introduction - The management and long-term outcome of patients affected by chronic myeloid leukemia...
Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result ...
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promis...
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder caused by BCR-ABL1 igureusion encod...
Since the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressi...
Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in mo...
The deregulated activity of BCR-ABL tyrosine kinase originating from the t(9;22) chromosomal translo...
Since the introduction of imatinib mesylate (IM) for the treatment of chronic myeloid leukemia (CML)...
In patients with chronic myeloid leukemia (CML) resistant to imatinib, resistance is commonly associ...
Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing t...
Resistance to imatinib is a significant clinical issue, and the underlying mechanism of this resista...
Mechanisms of resistance to tyrosin kinase inhibitors in treatment of patients with chronic myeloid ...
The BCR-ABL tyrosine kinase inhibitor Imatinib is highly effective for chronic myeloid leukemia (CML...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
none20noPURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associat...
Introduction - The management and long-term outcome of patients affected by chronic myeloid leukemia...
Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result ...
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promis...
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder caused by BCR-ABL1 igureusion encod...
Since the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressi...
Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in mo...
The deregulated activity of BCR-ABL tyrosine kinase originating from the t(9;22) chromosomal translo...
Since the introduction of imatinib mesylate (IM) for the treatment of chronic myeloid leukemia (CML)...
In patients with chronic myeloid leukemia (CML) resistant to imatinib, resistance is commonly associ...
Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing t...
Resistance to imatinib is a significant clinical issue, and the underlying mechanism of this resista...
Mechanisms of resistance to tyrosin kinase inhibitors in treatment of patients with chronic myeloid ...
The BCR-ABL tyrosine kinase inhibitor Imatinib is highly effective for chronic myeloid leukemia (CML...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
none20noPURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associat...
Introduction - The management and long-term outcome of patients affected by chronic myeloid leukemia...
Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result ...